IP Library › Granted Patent US 10,188,665
Granted Patent B2
US 10,188,665 · App. 15/818,089 · Granted Jan 29, 2019

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Inventors: Jeffrey L. Edelman (Irvine, CA); Kelly M. Harrison (Harker Heights, TX)
Assignee: Allergan, Inc.
A61K31/573A61K9/0048A61K9/0051A61K9/1647A61K31/56A61K31/728A61K47/34A61K47/36Y02A50/401
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,665
App. No.
15/818,089
Granted
Jan 29, 2019
Kind
B2
Abstract

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.

Claims (12)

1. An ophthalmic composition comprising: a therapeutically effective amount of a Glucocorticoid Derivative (GD) comprising an acyl group linked to C 17 , C 21 , or combination thereof via an ester linkage, and a viscosity-inducing component.

2. The composition of claim 1 wherein said GD has a lipophilicity greater than 2.53.

3. The composition of claim 1 wherein said GD has an aqueous solubility less than 10 mg/ml.

4. The composition of claim 1 , wherein the viscosity-inducing component comprises hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof.

5. The composition of claim 4 , wherein the viscosity-inducing component comprises a polymeric hyaluronate component.

6. The composition of claim 1 wherein said acyl group is selected from the group consisting of an acetyl, butyryl, valeryl, propionyl, furoyl, and benzoyl group.

7. The composition of claim 1 wherein said composition is suitable for administration to a patient by at least one of intravitreal administration and periocular administration.

8. The composition of claim 1 wherein said ophthalmic composition is an implant.

9. The composition of claim 8 wherein said implant further comprises a polymeric component.

10. The composition of claim 9 wherein said polymeric component is selected from the group consisting of poly (lactide-co-glycolide) polymer (PLGA), poly-lactic acid (PLA), poly-glycolic acid (PGA), polyesters, poly (ortho ester), poly(phosphazine), poly (phosphate ester), polycaprolactones, gelatin, and collagen, and derivatives and combinations thereof.

11. The composition of claim 1 , wherein the GD is beclomethasone propionate.

12. The composition of claim 1 , wherein the GD is beclomethasone dipropionate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: EDELMAN, JEFFREY L.; HARRISON, KELLY M.
To: ALLERGAN, INC.
Reel/Frame 046739/0194 →
Continuity (6)
Division 15043750 · Feb 15, 2016
Continuation 14463034 · Aug 19, 2014
Continuation 13299215 · Nov 17, 2011
Division 11550642 · Oct 18, 2006
Provisional Application 60728209 · Oct 18, 2005
Related Publication 20180125861A1 · May 10, 2018
Cited By (1)
US 12,509,469